Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.58 |
| ▸ | CA1 | P00915 | 4/20 | 0.58 |
| ▸ | CA2 | P00918 | 4/20 | 0.58 |
| ▸ | CA7 | P43166 | 4/20 | 0.58 |
| ▸ | CA9 | Q16790 | 4/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.58 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.57 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.57 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | PPIA | P62937 | 3/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13354976 | 0.84 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10414462 | 0.82 | CA1 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29954290 | 0.82 | ERN1 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13354975 | 0.81 | THRB (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL26317142 | 0.80 | CA12 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL24363631 | 0.78 | GAA (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3918261 | 0.78 | KDM4E (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8424844 | 0.76 | CA1 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23484386 | 0.76 | CYP3A4 (0.56) | THRBGAAALDH1A1MEN1MAPT | |
| SCHEMBL353666 | 0.76 | L3MBTL1 (0.46) | TAS1R3TAS1R1TAS1R2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4070795-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | Salk Institute for Biological Studies (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-3185868-B1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INST FOR BIOLOGICAL STUDI (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-2970315-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-09-15 | — | — | EP | disclosed |
| US-10774092-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-09-15 | — | — | US | disclosed |
| US-10722502-B2 | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10689397-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689397-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190284207-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-09-19 | — | — | US | disclosed |
| US-20190284207-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-09-19 | — | — | US | disclosed |
| US-20190255031-A1 | CRYSTALLINE POLYMORPHS OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-08-22 | — | — | US | disclosed |
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3185868-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | Salk Institute for Biological Studies (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016033100-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016033100-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-03-03 | — | — | WO | disclosed |
| US-7250249-B2 | Black and white photothermographic material | FUJIFILM CORPORATION (JP) | 2007-07-31 | — | — | US | disclosed |
| US-6972340-B2 | Selective protein tyrosine phosphatatase inhibitors | ABBOTT LABORATORIES (US) | 2005-12-06 | — | — | US | disclosed |
| WO-2003072537-A2 | SELECTIVE PROTEIN TYROSINE PHOSPHATATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003020688-A1 | SELECTIVE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-03-13 | — | — | WO | disclosed |
| US-20020169157-A1 | Selective protein tyrosine phosphatatase inhibitors | ABBOTT LABORATORIES | 2002-11-14 | — | — | US | disclosed |
| US-20020072516-A1 | Selective protein tyrosine phosphatatase inhibitors | ABBVIE INC. | 2002-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689397-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | CA12 4878/4885CA1 4828/4885CA2 4561/4885 |
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | CA12 4882/4885CA1 4860/4885CA2 4689/4885 |
| US-10722502-B2 | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | H1-0, H1-2, INF2 | CA12 2420/4885CA1 1126/4885CA2 1024/4885 |
| US-20190255031-A1 | CRYSTALLINE POLYMORPHS OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE | H1-0, H1-2, INF2 | CA12 2420/4885CA1 1126/4885CA2 1024/4885 |
| US-20020169157-A1 | Selective protein tyrosine phosphatatase inhibitors | PPM1B, PPM1A, PPM1D | CA12 3698/4885CA1 2248/4885CA2 1436/4885 |
| US-10774092-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | CA12 4878/4885CA1 4828/4885CA2 4561/4885 |
| US-20190284207-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | CA12 4882/4885CA1 4860/4885CA2 4689/4885 |
| US-20020072516-A1 | Selective protein tyrosine phosphatatase inhibitors | PPM1B, PPM1A, PPM1D | CA12 3698/4885CA1 2248/4885CA2 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.